Actavis
 |
|
| Subsidiary | |
| Industry | Branded and generic pharmaceuticals, and pharmaceutical research and development. |
| Founded | March 1984 in Libertyville, Illinois, United States |
| Founder | Allen Chao, Ph.D. and David Hsia, Ph.D. |
| Headquarters | Dublin, Ireland and Parsippany-Troy Hills, New Jersey, United States. |
|
Number of locations
|
40 manufacturing facilities, 27 global R&D centers and marketing/sales facilities worldwide. |
|
Area served
|
~100 Countries |
|
Key people
|
Brenton L. Saunders (CEO, President) Paul Bisaro, Executive Chairman |
| Products | Branded and generic pharmaceuticals |
| Revenue | US$ 13.062 billion(2014) |
 US$ 1.090 billion (2014) |
|
 -US$ 1.630 billion (2014) |
|
| Total assets |
US$ 6.881 billion (2014) |
| Total equity |
US$ 28.335 billion (2014) |
|
Number of employees
|
21,600 (Feb. 2015) |
| Parent | Teva Pharmaceuticals |
| Website | www |
Actavis Generics (formerly known as Watson Pharmaceuticals and Actavis, plc, prior to the acquisition of Allergan, inc) is a global pharmaceutical company focused on developing, manufacturing and commercializing branded pharmaceuticals, generic and over-the-counter medicines, and biologic products. Actavis has a commercial presence across approximately 100 countries. The company has global headquarters in Dublin, Ireland and administrative headquarters in Parsippany-Troy Hills, New Jersey, United States.
Actavis, plc markets brand products through six franchises in key therapeutic categories including: Aesthetics/Dermatology/Plastic Surgery; Neurosciences/CNS; Eye Care; Women’s Health and Urology; GI and Cystic Fibrosis; and Cardiovascular Disease and Infectious Disease. The company's products include Botox,Namenda, Restasis,Linzess, Bystolic, Juvederm,Latisse, Lo Loestrin Fe, Estrace, Teflaro, Dalvance, Ozurdex, Optive, Natrelle,Viibryd, Liletta, Saphris,Enablex, Actonel, Androderm, Gelnique and others.
...
Wikipedia